Germline STAT3 gain-of-function mutations in primary immunodeficiency: Impact on the cellular and clinical phenotype

Fisher, 1995, Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome, Cell, 81, 935, 10.1016/0092-8674(95)90013-6 Flanagan, 2014, Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease, Nat Genet, 46, 812, 10.1038/ng.3040 Haapaniemi, 2015, Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3, Blood, 125, 639, 10.1182/blood-2014-04-570101 Milner, 2015, Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations, Blood, 125, 591, 10.1182/blood-2014-09-602763 Morris, 2018, The molecular details of cytokine signaling via the JAK/STAT pathway, Protein Sci, 27, 1984, 10.1002/pro.3519 Silva, 2004, Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis, Oncogene, 23, 8017, 10.1038/sj.onc.1208159 Igaz, 2001, Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice, Inflamm Res, 50, 435, 10.1007/PL00000267 Ihle, 1997, Jaks and Stats in cytokine signaling, Stem Cell, 15, 105, 10.1002/stem.5530150814 O'Shea, 1997, Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet?, Immunity, 7, 1, 10.1016/S1074-7613(00)80505-1 Takeda, 1997, Targeted disruption of the mouse Stat 3 gene leads to early embryonic lethality, Proc Natl Acad Sci USA, 94, 3801, 10.1073/pnas.94.8.3801 Hillmer, 2016, STAT3 signaling in immunity, Cytokine Growth Factor Rev, 31, 1, 10.1016/j.cytogfr.2016.05.001 Holland, 2007, STAT3 mutations in the hyper-IgE syndrome, N Engl J Med, 357, 1608, 10.1056/NEJMoa073687 Minegishi, 2007, Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome, Nature, 448, 1058, 10.1038/nature06096 Fabre, 2019, Clinical aspects of STAT3 gain-of-function germline mutations: a systematic review, J Allergy Clin Immunol Pract, 7, 1958, 10.1016/j.jaip.2019.02.018 Jägle, 2020, Distinct molecular response patterns of activating STAT3 mutations associate with penetrance of lymphoproliferation and autoimmunity, Clin Immunol, 210, 108316, 10.1016/j.clim.2019.108316 Tanita, 2021, Clinical and immunological heterogeneity in Japanese patients with gain-of-function variants in STAT3, J Clin Immunol, 41, 780, 10.1007/s10875-021-00975-y Fabre, 2018, STAT3 gain of function: a new kid on the block in interstitial lung diseases, Am J Respir Crit Care Med, 197, e22, 10.1164/rccm.201707-1500IM Mauracher, 2020, Erythropoiesis defect observed in STAT3 GOF patients with severe anemia, J Allergy Clin Immunol, 145, 1297, 10.1016/j.jaci.2019.11.042 Velayos, 2017, An activating mutation in STAT3 results in neonatal diabetes through reduced insulin synthesis, Diabetes, 66, 1022, 10.2337/db16-0867 Sediva, 2017, Short Stature in a Boy with Multiple Early-Onset Autoimmune Conditions due to a STAT3 Activating Mutation: Could Intracellular Growth Hormone Signalling Be Compromised?, Horm Res Paediatr, 88, 160, 10.1159/000456544 Shah, 2018, T-cell receptor αβ+ and CD19+ cell-depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency, J Allergy Clin Immunol, 141, 1417, 10.1016/j.jaci.2017.07.008 Parlato, 2019, Efficacy of ruxolitinib therapy in a patient with severe enterocolitis associated with a STAT3 gain-of-function mutation, Gastroenterology, 156, 1206, 10.1053/j.gastro.2018.11.065 Todaro, 2019, Multisystem autoimmune disease caused by increased STAT3 phosphorylation and dysregulated gene expression, Haematologica, 104, e322, 10.3324/haematol.2018.202374 Gonzalez-Mancera, 2020, STAT3 gain-of-function mutation in a patient with pulmonary Mycobacterium abscessus infection, Respir Med Case Rep, 30, 101125 Terry, 2020, Prenatal autoimmune disease, multisystem, infantile onset-like phenotype and proximal renal tubular dysplasia associated with STAT3 mutation, Pediatr Dev Pathol, 23, 306, 10.1177/1093526619890734 Silva-Carmona, 2020, Successful treatment of interstitial lung disease in STAT3 gain-of-function using JAK inhibitors, Am J Respir Crit Care Med, 202, 893, 10.1164/rccm.201906-1204LE Sarfati, 2021, Life-saving, dose-adjusted, targeted therapy in a patient with a STAT3 gain-of-function mutation, J Clin Immunol, 41, 807, 10.1007/s10875-020-00914-3 Maccari, 2018, Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase δ syndrome: the European society for immunodeficiencies-activated phosphoinositide 3-kinase δ syndrome registry, Front Immunol, 9, 543, 10.3389/fimmu.2018.00543 Schwab, 2018, Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects, J Allergy Clin Immunol, 142, 1932, 10.1016/j.jaci.2018.02.055 Lorenzini, 2020, Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations, J Allergy Clin Immunol, 146, 901, 10.1016/j.jaci.2019.11.051 Velichko, 2002, STAT3 activation by type I interferons is dependent on specific tyrosines located in the cytoplasmic domain of interferon receptor chain 2c. Activation of multiple STATS proceeds through the redundant usage of two tyrosine residues, J Biol Chem, 277, 35635, 10.1074/jbc.M204578200 Kwon, 2009, Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors, Immunity, 31, 941, 10.1016/j.immuni.2009.10.008 Vallania, 2009, Genome-wide discovery of functional transcription factor binding sites by comparative genomics: the case of Stat 3, Proc Natl Acad Sci USA, 106, 5117, 10.1073/pnas.0900473106 Wen, 1995, Maximal activation of transcription by Stat 1 and Stat 3 requires both tyrosine and serine phosphorylation, Cell, 82, 241, 10.1016/0092-8674(95)90311-9 Wingelhofer, 2018, Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer, Leukemia, 32, 1713, 10.1038/s41375-018-0117-x Carow, 2014, SOCS3, a major regulator of infection and inflammation, Front Immunol, 5, 58, 10.3389/fimmu.2014.00058 Chung, 1997, Specific inhibition of Stat 3 signal transduction by PIAS3, Science, 278, 1803, 10.1126/science.278.5344.1803 Roca Suarez, 2018, Viral manipulation of STAT3: evade, exploit, and injure, PLoS Pathog, 14, 10.1371/journal.ppat.1006839 Cheon, 2011, The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins, J Interferon Cytokine Res, 31, 33, 10.1089/jir.2010.0100 Huynh, 2019, Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map, Nat Rev Canc, 19, 82, 10.1038/s41568-018-0090-8 Wegrzyn, 2009, Function of mitochondrial Stat 3 in cellular respiration, Science, 323, 793, 10.1126/science.1164551 Gough, 2009, Mitochondrial STAT3 supports Ras-dependent oncogenic transformation, Science, 324, 1713, 10.1126/science.1171721 Jerez, 2012, STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia, Blood, 120, 3048, 10.1182/blood-2012-06-435297 Veitia, 2018, Mechanisms of mendelian dominance, Clin Genet, 93, 419, 10.1111/cge.13107 Vogel, 2015, The ying and yang of STAT3 in human disease, J Clin Immunol, 35, 615, 10.1007/s10875-015-0187-8 Wan, 2015, Opposing roles of STAT1 and STAT3 in IL-21 function in CD4+ T cells, Proc Natl Acad Sci USA, 112, 9394, 10.1073/pnas.1511711112 Sadreev, 2018, The competitive nature of signal transducer and activator of transcription complex formation drives phenotype switching of T cells, Immunology, 153, 488, 10.1111/imm.12851 Novak, 1996, Formation of STAT5-containing DNA binding complexes in response to colony-stimulating factor-1 and platelet-derived growth factor, J Biol Chem, 271, 18350, 10.1074/jbc.271.31.18350 Kanai, 2012, The stat5b pathway defect and autoimmunity, Front Immunol, 3, 234, 10.3389/fimmu.2012.00234 Gutiérrez, 2018, Partial growth hormone insensitivity and dysregulatory immune disease associated with de novo germline activating STAT3 mutations, Mol Cell Endocrinol, 473, 166, 10.1016/j.mce.2018.01.016 Rawlings, 2004, The JAK/STAT signaling pathway, J Cell Sci, 117, 1281, 10.1242/jcs.00963 Zhang, 2013, Mitochondrial localized Stat 3 promotes breast cancer growth via phosphorylation of serine 727, J Biol Chem, 288, 31280, 10.1074/jbc.M113.505057 Raja, 2020, Clin Cancer Res Zhang, 2014, STAT3 in cancer-friend or foe?, Cancers, 6, 1408, 10.3390/cancers6031408 Deenick, 2018, Signal transducer and activator of transcription 3 control of human T and B cell responses, Front Immunol, 9, 168, 10.3389/fimmu.2018.00168 Yang, 2007, STAT3 regulates cytokine-mediated generation of inflammatory helper T cells, J Biol Chem, 282, 9358, 10.1074/jbc.C600321200 Wu, 2016, Stat 3 is important for follicular regulatory T cell differentiation, PLoS One, 11 Yang, 2008, Molecular antagonism and plasticity of regulatory and inflammatory T cell programs, Immunity, 29, 44, 10.1016/j.immuni.2008.05.007 Fornek, 2006, Critical role for Stat 3 in T-dependent terminal differentiation of IgG B cells, Blood, 107, 1085, 10.1182/blood-2005-07-2871 Nabhani, 2017, STAT3 gain-of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic compounds, Clin Immunol, 181, 32, 10.1016/j.clim.2017.05.021 Kimura, 2004, SOCS3 is a physiological negative regulator for granulopoiesis and granulocyte colony-stimulating factor receptor signaling, J Biol Chem, 279, 6905, 10.1074/jbc.C300496200 Owen, 2017, STAT5 and CD4 + T cell immunity, F1000Res, 6, 32, 10.12688/f1000research.9838.1 Pillemer, 2007, Deficient SOCS3 expression in CD4+CD25+FoxP3+ regulatory T cells and SOCS3-mediated suppression of Treg function, Eur J Immunol, 37, 2082, 10.1002/eji.200737193 Carpenter, 2014, STAT3 target genes relevant to human cancers, Cancers, 6, 897, 10.3390/cancers6020897 Turkson, 2000, STAT proteins: novel molecular targets for cancer drug discovery, Oncogene, 19, 6613, 10.1038/sj.onc.1204086 Xiong, 2014, Transcription factor STAT3 as a novel molecular target for cancer prevention, Cancers, 6, 926, 10.3390/cancers6020926 Segatto, 2018, STAT3 in breast cancer onset and progression: a matter of time and context, Int J Mol Sci, 19, 9, 10.3390/ijms19092818 Koskela, 2012, Somatic STAT3 mutations in large granular lymphocytic leukemia, N Engl J Med, 366, 1905, 10.1056/NEJMoa1114885 Andersson, 2013, Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation, Blood Canc J, 3, e168, 10.1038/bcj.2013.65 Jerez, 2013, STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients, Blood, 122, 2453, 10.1182/blood-2013-04-494930 Rajala, 2014, Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations, Ann Med, 46, 114, 10.3109/07853890.2014.882105 Lamy, 1998, Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia, Blood, 92, 4771, 10.1182/blood.V92.12.4771 Epling-Burnette, 2001, Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression, J Clin Invest, 107, 351, 10.1172/JCI9940 Shah, 2008, Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes, Blood, 112, 770, 10.1182/blood-2007-11-121871 Gutiérrez, 2020, Activating mutations of STAT3: impact on human growth, Mol Cell Endocrinol, 518, 110979, 10.1016/j.mce.2020.110979 Ray, 2013, The IL-6 trans-signaling-STAT3 pathway mediates ECM and cellular proliferation in fibroblasts from hypertrophic scar, J Invest Dermatol, 133, 1212, 10.1038/jid.2012.499 Papaioannou, 2018, STAT3 controls COL1A2 enhancer activation cooperatively with JunB, regulates type I collagen synthesis posttranscriptionally, and is essential for lung myofibroblast differentiation, Mol Biol Cell, 29, 84, 10.1091/mbc.E17-06-0342 Pechkovsky, 2012, STAT3-mediated signaling dysregulates lung fibroblast-myofibroblast activation and differentiation in UIP/IPF, Am J Pathol, 180, 1398, 10.1016/j.ajpath.2011.12.022 Knight, 2011, STAT3 in tissue fibrosis: is there a role in the lung?, Pulm Pharmacol Therapeut, 24, 193, 10.1016/j.pupt.2010.10.005 Prêle, 2012, STAT3: a central mediator of pulmonary fibrosis?, Proc Am Thorac Soc, 9, 177, 10.1513/pats.201201-007AW Kasembeli, 2018, Contribution of STAT3 to inflammatory and fibrotic diseases and prospects for its targeting for treatment, Int J Mol Sci, 19, 2299, 10.3390/ijms19082299 Dees, 2020, TGF-β-induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis, J Clin Invest, 130, 2347, 10.1172/JCI122462 Tangye, 2017, Low IgE is insufficiently sensitive to guide genetic testing of STAT3 gain-of-function mutations, Clin Chem, 63, 1539, 10.1373/clinchem.2017.273458 Fusaro, 2021, Improving the diagnostic efficiency of primary immunodeficiencies with targeted next-generation sequencing, J Allergy Clin Immunol, 147, 734, 10.1016/j.jaci.2020.05.046 Maffucci, 2016, Genetic diagnosis using whole exome sequencing in common variable immunodeficiency, Front Immunol, 7, 220, 10.3389/fimmu.2016.00220 Forbes, 2018, Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations, J Allergy Clin Immunol, 142, 1665, 10.1016/j.jaci.2018.07.020 Russell, 2018, A novel de novo activating mutation in STAT3 identified in a patient with common variable immunodeficiency (CVID), Clin Immunol, 187, 132, 10.1016/j.clim.2017.11.007 Wienke, 2015, A novel human STAT3 mutation presents with autoimmunity involving Th17 hyperactivation, Oncotarget, 6, 20037, 10.18632/oncotarget.5042 Weinreich, 2017, Up, down, and all around: diagnosis and treatment of novel STAT3 variant, Front Pediatr, 5, 49, 10.3389/fped.2017.00049 Besnard, 2018, Pediatric-onset Evans syndrome: heterogeneous presentation and high frequency of monogenic disorders including LRBA and CTLA4 mutations, Clin Immunol, 188, 52, 10.1016/j.clim.2017.12.009 Giovannini-Chami, 2019, STAT3 gain of function: a new aetiology of severe rheumatic disease, Rheumatology, 58, 365, 10.1093/rheumatology/key308 Khoury, 2017, Tocilizumab promotes regulatory T-cell alleviation in STAT3 gain-of-function-associated multi-organ autoimmune syndrome, Clin Therapeut, 39, 444, 10.1016/j.clinthera.2017.01.004 Bakhtiar, 2019, Allogeneic hematopoietic stem cell transplantation for congenital immune dysregulatory disorders, Front Pediatr, 7, 461, 10.3389/fped.2019.00461 Hadjadj, 2020, Early-onset autoimmunity associated with SOCS1 haploinsufficiency, Nat Commun, 11, 5341, 10.1038/s41467-020-18925-4 Walker, 2016, Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome, Blood, 127, 948, 10.1182/blood-2015-06-654277 Fernandez-Pol, 2021, Two cases with features of lymphocyte variant hypereosinophilic syndrome with STAT3 SH2 domain mutations, Am J Surg Pathol, 45, 193, 10.1097/PAS.0000000000001604